HomeCompareAMGN vs NOW

AMGN vs NOW: Dividend Comparison 2026

AMGN yields 2.77% · NOW yields 1.91%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMGN wins by $141.7K in total portfolio value
10 years
AMGN
AMGN
● Live price
2.77%
Share price
$349.00
Annual div
$9.66
5Y div CAGR
48.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$164.2K
Annual income
$69,743.86
Full AMGN calculator →
NOW
NOW
● Live price
1.91%
Share price
$104.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.5K
Annual income
$215.52
Full NOW calculator →

Portfolio growth — AMGN vs NOW

📍 AMGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMGNNOW
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMGN + NOW cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMGN pays
NOW pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMGN
Annual income on $10K today (after 15% tax)
$235.27/yr
After 10yr DRIP, annual income (after tax)
$59,282.28/yr
NOW
Annual income on $10K today (after 15% tax)
$161.95/yr
After 10yr DRIP, annual income (after tax)
$183.19/yr
At 15% tax rate, AMGN beats the other by $59,099.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMGN + NOW for your $10,000?

AMGN: 50%NOW: 50%
100% NOW50/50100% AMGN
Portfolio after 10yr
$93.3K
Annual income
$34,979.69/yr
Blended yield
37.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NOW right now

AMGN
Analyst Ratings
22
Buy
13
Hold
3
Sell
Consensus: Buy
Price Target
$347.73
-0.4% upside vs current
Range: $185.00 — $432.00
Altman Z
2.3
Piotroski
8/9
NOW
Analyst Ratings
58
Buy
8
Hold
1
Sell
Consensus: Buy
Price Target
$196.29
+87.0% upside vs current
Range: $115.00 — $263.00
Altman Z
6.1
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMGN buys
0
NOW buys
14
PoliticianChamberTickerTypeAmountDate
Charles J. "Chuck" Fleischmann🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-20
Byron Donalds🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-10
Byron Donalds🏢 House$NOW▲ Buy$1,001 - $15,0002026-02-10
Tony Wied🏢 House$NOW▲ Buy$15,001 - $50,0002026-02-04
Josh Gottheimer🏢 House$NOW▼ Sell$1,001 - $15,0002026-01-30
Markwayne Mullin🏛 Senate$NOW▲ Buy$15,001 - $50,0002025-12-29
Markwayne Mullin🏛 Senate$NOW▲ Buy$15,001 - $50,0002025-12-29
Josh Gottheimer🏢 House$NOW▼ Sell$1,001 - $15,0002025-12-17
Julie Johnson🏢 House$NOW▼ Sell$1,001 - $15,0002025-12-09
Michael McCaul🏢 House$NOW▲ Buy$1,001 - $15,0002025-10-31
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMGNNOW
Forward yield2.77%1.91%
Annual dividend / share$9.66$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR48.6%0%
Portfolio after 10y$164.2K$22.5K
Annual income after 10y$69,743.86$215.52
Total dividends collected$133.8K$2.0K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$347.73$196.29

Year-by-year: AMGN vs NOW ($10,000, DRIP)

YearAMGN PortfolioAMGN Income/yrNOW PortfolioNOW Income/yrGap
1← crossover$11,111$411.31$10,891$190.53+$220.00AMGN
2$12,524$634.70$11,847$193.92+$677.00AMGN
3$14,394$993.52$12,873$197.15+$1.5KAMGN
4$16,987$1,585.83$13,975$200.22+$3.0KAMGN
5$20,776$2,599.19$15,156$203.13+$5.6KAMGN
6$26,645$4,414.70$16,423$205.89+$10.2KAMGN
7$36,373$7,863.06$17,781$208.50+$18.6KAMGN
8$53,826$14,907.12$19,236$210.97+$34.6KAMGN
9$88,231$30,636.84$20,796$213.31+$67.4KAMGN
10$164,151$69,743.86$22,468$215.52+$141.7KAMGN

AMGN vs NOW: Complete Analysis 2026

AMGNHealthcare

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Full AMGN Calculator →

NOWStock

ServiceNow, Inc. provides enterprise cloud computing solutions that defines, structures, consolidates, manages, and automates services for enterprises worldwide. It operates the Now platform for workflow automation, artificial intelligence, machine learning, robotic process automation, performance analytics, electronic service catalogs and portals, configuration management systems, data benchmarking, encryption, and collaboration and development tools. The company also provides information technology (IT) service management applications; IT service management product suite for enterprise's employees, customers, and partners; IT business management product suite; IT operations management product that connects a customer's physical and cloud-based IT infrastructure; IT Asset Management to automate IT asset lifecycles; and security operations that connects with internal and third party. In addition, it offers governance, risk, and compliance product to manage risk and resilience; human resources, legal, and workplace service delivery products; safe workplace applications; customer service management product; and field service management applications. Further, it provides App Engine product; IntegrationHub enables application to extend workflows; and professional, industry solutions, and customer support services. It serves government, financial services, healthcare, telecommunications, manufacturing, IT services, technology, oil and gas, education, and consumer products through direct sales team and resale partners. It has a strategic partnership with Celonis to help customers identify and prioritize processes that are suitable for automation. The company was formerly known as Service-now.com and changed its name to ServiceNow, Inc. in May 2012. The company was founded in 2004 and is headquartered in Santa Clara, California.

Full NOW Calculator →
📬

Get this AMGN vs NOW comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMGN vs SCHDAMGN vs JEPIAMGN vs OAMGN vs KOAMGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.